Dear OHDSI community,
This is a broad call for inviting collaborators (especially data partners) for exciting research on replicating clinical trials based on the OHDSI network.
Last year we (@Jaehyeong_Cho, @Chungsoo_Kim, @kyulee.jeon, and @SCYou) initiated a project related to key issues pointed out by many observational researchers.
- Different clinical characteristics between RCT and RWD patients with similar eligibility criteria
- Controversial generalizability of RCT effects in real clinical settings.
Therefore, through this TROY study, we would like to investigate the following three points based on multiple OMOP CDM databases.
- Proportion of patients meeting eligibility criteria among patients with FDA-approved indications
- Comparison of differences in clinical characteristics between clinical trial patients and patients extracted from actual data
- Comparative analysis of efficacy between target drug and reference drug (experimental emulation)
We look forward to the active participation of data partners, and we will set up a meeting to outline the study once an appropriate number of data partners have been recruited. (Even if you don’t have OMOPed data, please feel free to contact us about how you can participate in this study.)
For more information, please see the Study Repo, Protocol, Selected clinical trial information, and 2022 OHDSI Symposium video.
If you are interested or have any questions, please comment on this thread or please contact us via email → ted9219@ajou.ac.kr
Thank you
Chungsoo Kim